Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,750.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPHGet Free Report) insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00. Following the completion of the sale, the insider owned 250,780 shares of the company’s stock, valued at $1,241,361. This trade represents a 1.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

  • On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.82, for a total transaction of $24,100.00.
  • On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.20, for a total transaction of $3,161.60.
  • On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $7,936.00.
  • On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,944.00.
  • On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.68, for a total transaction of $17,433.00.
  • On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,152.94.
  • On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
  • On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,688.00.
  • On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $13,095.00.
  • On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $2,912.32.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH opened at $4.78 on Thursday. The firm has a 50 day moving average of $4.94 and a 200-day moving average of $4.85. The stock has a market capitalization of $327.38 million, a PE ratio of -9.19 and a beta of 0.98. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 12 month low of $2.59 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPHGet Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

View Our Latest Research Report on SOPH

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently made changes to their positions in the stock. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS during the 1st quarter valued at approximately $50,000. Savvy Advisors Inc. bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $48,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $49,000. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at approximately $49,000. Finally, Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at approximately $54,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

See Also

Insider Buying and Selling by Quarter for SOPHiA GENETICS (NASDAQ:SOPH)

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.